相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas
Linfeng Chen et al.
HAEMATOLOGICA (2020)
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
Franziska M. Ippen et al.
CLINICAL CANCER RESEARCH (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
Hironobu Minami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
Fevzi F. Yalniz et al.
DRUGS (2019)
The whole-genome landscape of Burkitt lymphoma subtypes
Razvan I. Panea et al.
BLOOD (2019)
Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy
Anna C. Beielstein et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma
Bruno M. Grande et al.
BLOOD (2019)
A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
Masanori Toyoda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu et al.
HAEMATOLOGICA (2019)
PubChem 2019 update: improved access to chemical data
Sunghwan Kim et al.
NUCLEIC ACIDS RESEARCH (2019)
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
Janice M. Mehnert et al.
INVESTIGATIONAL NEW DRUGS (2018)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Bispecific antibodies in haematological malignancies
Andreas Viardot et al.
CANCER TREATMENT REVIEWS (2018)
Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
Li Tian et al.
DRUG DELIVERY (2018)
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Andreas Wicki et al.
EUROPEAN JOURNAL OF CANCER (2018)
PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment
Xiaoyan Liu et al.
FUTURE ONCOLOGY (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Acute leukemia cells resistant to PI3K/ mTOR inhibition display upregulation of P2RY14 expression
Kinjal Shah et al.
CLINICAL EPIGENETICS (2018)
mTOR at the Transmitting and Receiving ends in Tumor immunity
Yakir Guri et al.
FRONTIERS IN IMMUNOLOGY (2018)
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
Jennifer R. Brown et al.
LANCET HAEMATOLOGY (2018)
Cell-Penetrating CaCO3 Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma
Viviana Vergaro et al.
CANCERS (2018)
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Fabiana Conciatori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers
Jiao Yuan et al.
CANCER CELL (2018)
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli et al.
CLINICAL CANCER RESEARCH (2018)
GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy
Juan Gu et al.
BLOOD (2018)
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
The ChEMBL database in 2017
Anna Gaulton et al.
NUCLEIC ACIDS RESEARCH (2017)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei et al.
ONCOLOGIST (2017)
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Zev A. Wainberg et al.
TARGETED ONCOLOGY (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
460PPHASE I CLINICAL TRIAL OF DS-7423, AN ORAL PI3K/MTOR DUAL INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
T. Yokota et al.
ANNALS OF ONCOLOGY (2017)
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Filip Janku
CANCER TREATMENT REVIEWS (2017)
Tonic B-cell receptor signaling in diffuse large B-cell lymphoma
Ondrej Havranek et al.
BLOOD (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)
Mohiuddin Gazi et al.
CANCER LETTERS (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Pamela Munster et al.
CLINICAL CANCER RESEARCH (2016)
PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas
Deyu Chen et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
R. Thijssen et al.
LEUKEMIA (2016)
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies
Farrukh T. Awan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Saoirse O. Dolly et al.
CLINICAL CANCER RESEARCH (2016)
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Josep Maria del Campo et al.
GYNECOLOGIC ONCOLOGY (2016)
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
J. E. Grilley-Olson et al.
INVESTIGATIONAL NEW DRUGS (2016)
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
Zhen Jin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma
Kai Qing et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells
Annette K. Brenner et al.
MOLECULES (2016)
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
O. Lindblad et al.
ONCOGENE (2016)
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo et al.
ONCOLOGIST (2016)
Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma
Wei Ju et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Timothy P. Heffron et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
Scott A. Ezell et al.
ONCOTARGET (2016)
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
Pei Shi Ong et al.
FRONTIERS IN PHARMACOLOGY (2016)
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Sherri Z. Millis et al.
JAMA ONCOLOGY (2016)
A first-in-human phase 1 study to evaluate the brain penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma
Thomas Ippolito et al.
BLOOD (2016)
A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma
Graham P. Collins et al.
BLOOD (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
Kimberly Blackwell et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice
Yinfei Tan et al.
CANCER BIOLOGY & THERAPY (2015)
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Johanna C. Bendell et al.
INVESTIGATIONAL NEW DRUGS (2015)
ZINC 15-Ligand Discovery for Everyone
Teague Sterling et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
J. Scott Lee et al.
ONCOTARGET (2015)
Activity of BKM120 and BEZ235 against Lymphoma Cells
Monica Civallero et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma
Penny Anders et al.
LEUKEMIA & LYMPHOMA (2015)
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
Kyriakos P. Papadopoulos et al.
LEUKEMIA & LYMPHOMA (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Antje Dittmann et al.
ACS CHEMICAL BIOLOGY (2014)
Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine
Cedric Leroy et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
Erika K. Keeton et al.
BLOOD (2014)
Constitutive AKT activation in follicular lymphoma
Ouardia I. Yahiaoui et al.
BMC CANCER (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2014)
PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1-Dependent Mechanisms In Vitro and In Vivo
Mohamed Rahmani et al.
CLINICAL CANCER RESEARCH (2014)
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten et al.
INVESTIGATIONAL NEW DRUGS (2014)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
Pasi A. Jaenne et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Peiwen Yu et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110 delta result in T cell senescence and human immunodeficiency
Carrie L. Lucas et al.
NATURE IMMUNOLOGY (2014)
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells
Lesley A. Mathews Griner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
Sunil Iyengar et al.
BLOOD (2013)
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo
Pradip De et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
Chuanbing Zang et al.
CANCER LETTERS (2013)
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Katherine Walsh et al.
CLINICAL CANCER RESEARCH (2013)
Long-term p110 PI3K inactivation exerts a beneficial effect on metabolism
Lazaros C. Foukas et al.
EMBO MOLECULAR MEDICINE (2013)
Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
Guillermo A. Morales et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia
Zhi-Jian Zou et al.
LEUKEMIA & LYMPHOMA (2013)
Memory of Conditioned Taste Aversion Is Erased by Inhibition of PI3K in the Insular Cortex
Ilana Slouzkey et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
Matthias Pfeifer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms
Mohamed Rahmani et al.
BLOOD (2013)
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B. Markman et al.
ANNALS OF ONCOLOGY (2012)
Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
Michael Y. Choi et al.
CANCER JOURNAL (2012)
The Chemical Biology of Phosphoinositide 3-Kinases
Matthias P. Wymann et al.
CHEMBIOCHEM (2012)
Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Jennifer R. Brown et al.
CLINICAL CANCER RESEARCH (2012)
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
D. Mahadevan et al.
EUROPEAN JOURNAL OF CANCER (2012)
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
Monica Civallero et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
Areumnuri Kim et al.
LEUKEMIA RESEARCH (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
The genetic landscape of mutations in Burkitt lymphoma
Cassandra Love et al.
NATURE GENETICS (2012)
Small molecules targeting phosphoinositide 3-kinases
Peng Wu et al.
MEDCHEMCOMM (2012)
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
Alberto M. Martelli et al.
ONCOTARGET (2012)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James A. McCubrey et al.
ONCOTARGET (2012)
Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies
John G. Foster et al.
PHARMACOLOGICAL REVIEWS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Robert Mallon et al.
CLINICAL CANCER RESEARCH (2011)
Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
D. A. Sabbah et al.
CURRENT MEDICINAL CHEMISTRY (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
Eduardo Vilar et al.
MOLECULAR CANCER THERAPEUTICS (2011)
PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
David A. Fruman et al.
CANCER DISCOVERY (2011)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor
Aranapakam M. Venkatesan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
P. M. Bhende et al.
LEUKEMIA (2010)
PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma
Yan-Yan Liu et al.
LEUKEMIA & LYMPHOMA (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α
Minghao Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85 alpha subunit of phosphoinositide-3 kinase
Chihiro Tohda et al.
BRAIN & DEVELOPMENT (2009)
Phosphatidylinositol 3′-Kinase Catalytic Subunit α Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
Amanda Psyrri et al.
CLINICAL CANCER RESEARCH (2009)
Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia
Millaray Marincevic et al.
LEUKEMIA & LYMPHOMA (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
Joseph R. Garlich et al.
CANCER RESEARCH (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma
Yu Baohua et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2008)
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma
J. Abubaker et al.
LEUKEMIA (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer
Stephen G. Dann et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Shahab Uddin et al.
BLOOD (2006)
Loss of class IAPI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia
Ji Luo et al.
CELL METABOLISM (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Cancer-specific mutations in PIK3CA are oncogenic in vivo
AG Bader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase
S Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Loss of class I(A)PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia
Ji Luo et al.
CELL (2006)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes
DA Fruman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
